Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Capricor Therap (NQ: CAPR )

18.62 +0.83 (+4.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therap

< Previous 1 2 3 4 Next >
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Capricor Therapeutics partners with Nippon Shinyaku for the European commercialization of Duchenne muscular dystrophy treatment, deramiocel, with a potential $1.5 billion in milestone payments from... 
Via Benzinga
Unveiling 6 Analyst Insights On Capricor Therapeutics
Via Benzinga
What's Going On With Capricor Therapeutics Stock Friday?
The biotechnology company said deramiocel increased cardiac function based on several different measures. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA). 
Via Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension 
Via Benzinga
Expert Ratings For Capricor Therapeutics
Via Benzinga
Recap: Capricor Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024
CAPR stock results show that Capricor Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Capricor Therapeutics's Earnings Outlook
Via Benzinga
Preview: Capricor Therapeutics's Earnings
Via Benzinga
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Turn Lower; Dow Tumbles Over 200 Points
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 while the NASDAQ fell 0.15% to 13,181.22. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Capricor Therapeutics Q1 Earnings
Via Benzinga
Earnings Preview For Capricor Therapeutics
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Crude Oil Down 1% Following PCE Data; Blue Apron Shares Surge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74 while the NASDAQ rose 0.99% to 13,331.54. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
Via Benzinga
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
Capricor Initiates Late-Stage Neuropsychiatric Disorder Study
Capricor Therapeutics (NASDAQ: CAPR) initiated dosing of first patient in HOPE-3, a Phase 3 clinical trial investigating CAP-1002 for treating late-stage Duchenne muscular dystrophy (DMD). 
Via Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.